NW Bio announced today that the Company will be making a joint - TopicsExpress



          

NW Bio announced today that the Company will be making a joint poster presentation today, November 7th relating to its DCVax-Direct Phase I/II Trial for inoperable solid tumor cancers at the 29th Annual Meeting of the Society For Immunotherapy of Cancer (SITC). The presentation will focus on case studies demonstrating a range of clinical effects of the direct injection of a patient’s partially activated dendritic cells into inoperable tumors to generate both local and generalized anti-tumor immune responses. Commenting on the case studies to be presented, Dr. Marnix Bosch, Chief Technical Officer of NW Bio and senior author of the poster said, We are looking forward to building upon this learning as we initiate the Phase II stage of this trial in the near future, while we also continue gathering data from the patients continuing to be treated in the Phase I portion of the trial. bit.ly/1ydHnI5
Posted on: Fri, 07 Nov 2014 18:05:05 +0000

Trending Topics



Recently Viewed Topics




© 2015